Literature DB >> 2423641

Detection of cytomegalovirus by ELISA in urine samples is inhibited by beta 2 microglobulin.

J A McKeating, J E Grundy, Z Varghese, P D Griffiths.   

Abstract

During development of an enzyme immunoassay for the detection of cytomegalovirus (CMV) we previously discovered that virus found naturally in urine specimens could not be captured onto the solid phase by CMV-specific monoclonal antibodies, whereas these same antibodies could capture CMV from cell culture supernatants. We now report that urine from normal CMV-seronegative individuals contains a substance of molecular weight 11-12,000 daltons that inhibits the ELISA detection of cell culture-grown CMV. The addition of a known urinary protein of this molecular weight, beta 2 microglobulin (beta 2m; 11,700 daltons), inhibited the detection of cell culture-grown CMV in the ELISA over the concentration range found in clinical urine samples. In contrast, another low molecular weight urinary protein, lysozyme, had no inhibitory effect. beta 2m caused inhibition only when added to the virus preparation and not to the antibody-capture stage. We conclude that beta 2m in urine prevents the detection of CMV by ELISA by binding to the virus and masking its antigenic determinants and we calculate that of the order of 10(5) molecules of beta 2m bind to each particle of cell culture-grown CMV. We postulate that CMV in fresh urine specimens is similarly coated with beta 2m, accounting for the failure to detect it by ELISA.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2423641     DOI: 10.1002/jmv.1890180407

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  10 in total

Review 1.  Diagnosis of cytomegalovirus infection: a review.

Authors:  D Pillay; P D Griffiths
Journal:  Genitourin Med       Date:  1992-06

2.  Detection of cytomegalovirus in urine samples by an enzyme-linked immunosorbent assay using a monoclonal antibody against the viral 150-kilodalton protein.

Authors:  T Yamanaka; K Kiyotani; T Sakaguchi; Y Fukuda; K Dohi; M Yamada; M Yoshida; S Nii; T Yoshida
Journal:  J Clin Microbiol       Date:  1992-03       Impact factor: 5.948

3.  Cytomegalovirus Virions Shed in Urine Have a Reversible Block to Epithelial Cell Entry and Are Highly Resistant to Antibody Neutralization.

Authors:  Xiaohong Cui; Stuart P Adler; Mark R Schleiss; Ravit Arav-Boger; Gail J Demmler Harrison; Michael A McVoy
Journal:  Clin Vaccine Immunol       Date:  2017-06-05

Review 4.  Molecular biology and immunology of cytomegalovirus.

Authors:  P D Griffiths; J E Grundy
Journal:  Biochem J       Date:  1987-01-15       Impact factor: 3.857

5.  Dot immunoperoxidase assay using monoclonal antibody for direct detection of cytomegalovirus in urine samples.

Authors:  M Zerbini; M Musiani; G Gentilomi; M La Placa
Journal:  J Clin Microbiol       Date:  1987-11       Impact factor: 5.948

6.  Functional changes in murine macrophages infected with cytomegalovirus relate to H-2-determined sensitivity to infection.

Authors:  P Price; J G Winter; S Nikoletti; J B Hudson; G R Shellam
Journal:  J Virol       Date:  1987-11       Impact factor: 5.103

7.  Human cytomegalovirus binding to fibroblasts is receptor mediated.

Authors:  H P Taylor; N R Cooper
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

8.  Cell membrane bound N-acetylneuraminic acid is involved in the infection of fibroblasts and phorbol-ester differentiated monocyte-like cells with human cytomegalovirus (HCMV).

Authors:  P E Lobert; D Hober; A Dewilde; P Wattré
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

9.  The effects of beta-2-microglobulin on the infectivity of murine cytomegalovirus.

Authors:  M N Wykes; P Price; G R Shellam
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

10.  Human cytomegalovirus entry into dendritic cells occurs via a macropinocytosis-like pathway in a pH-independent and cholesterol-dependent manner.

Authors:  Fabienne Haspot; Amélie Lavault; Christian Sinzger; Kerstin Laib Sampaio; York-Dieter Stierhof; Paul Pilet; Céline Bressolette-Bodin; Franck Halary
Journal:  PLoS One       Date:  2012-04-09       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.